Table 2.

Univariate and multivariate analysis of TMEM176A methylation status with 3 year-overall survival (OS) in HCC patients

Clinical factor	3-year OS
	Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.204	0.557
(< 60 vs. ≥ 60 years)	(0.649–2.235)
Gender	0.869	0.775
(Male vs. female)	(0.331–2.282)
TMEM176A	2.388	0.027*	2.370	0.025*
(Methylation vs. unmethylation)	(1.102–5.175)		(1.116–5.034)
HBV infection	0.592	0.142
(YES vs. NO)	(0.294–1.191)
Liver cirrhosis	1.360	0.401
(Yes vs. no)	(0.664–2.784)
Tumor size	1.184	0.670
(≤ 5 cm vs. > 5 cm)	(0.544–2.580)
Number of lesions	0.902	0.793
(1 vs. ≥ 1)	(0.419–1.944)
Differentiation	2.212	0.020*	1.989	0.015*
(Well or moderate vs. poor)	(1.133–4.320)		(1.140–3.470)
TNM stage	1.150	0.724
(Stage I + stage II vs. stage III + stage IV)	(0.528–2.505)
Lymph node metastasis	1.184	0.670
(Negative vs. positive)	(0.544–2.580)
Vessel cancerous embolus	0.444	0.025*	0.441	0.006**
(Negative vs. positive)	(0.219–0.902)		(0.245–0.794)

HR hazard ratio

*P < 0.05; **P < 0.01